Bradley Foster & Sargent’s Ionis Pharmaceuticals IONS Stock Holding History

Bradley Foster & Sargent’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-17,050	Closed	-$632K	–	454
2022 Q1	$632K	Buy	+17,050	New	+$558K	0.01%	320
2021 Q1	–	Sell	-21,077	Closed	-$1.19M	–	381
2020 Q4	$1.19M	Buy	+21,077	New	+$1.05M	0.03%	211
2020 Q1	$38K	Sell	804 -295	-27%	-$16.4K	﹤0.01%	326
2019 Q4	$66K	Buy	1,099 +295	+37%	+$17.6K	﹤0.01%	356
2019 Q3	$49K	Buy	+804	New	+$52.4K	﹤0.01%	342
2019 Q2	–	Sell	-24,877	Closed	-$2.02M	–	354
2019 Q1	$2.02M	Buy	+24,877	New	+$1.6M	0.07%	164
2018 Q2	–	Sell	-6,724	Closed	-$296K	–	369
2018 Q1	$296K	Buy	+6,724	New	+$342K	0.01%	309

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TBC

Tweedy, Browne Co Stamford, Connecticut $1.26B AUM 33.88% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Bradley Foster & Sargent's IONS Position: Q2 2022 in Review

Bradley Foster & Sargent sold out of Ionis Pharmaceuticals (IONS) in Q2 2022, closing a stake of 17,050 shares — an estimated $632K sold.

Bradley Foster & Sargent first reported a position in IONS in Q1 2018 and held it in 7 quarters. The position peaked at $2.02M in Q1 2019. 349 funds tracked by Wall St. Rank hold IONS as of Q2 2022.

Bradley Foster & Sargent reported no remaining Ionis Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Bradley Foster & Sargent sold 17,050 Ionis Pharmaceuticals shares in Q2 2022, an estimated $632K.
Bradley Foster & Sargent first reported a position in Ionis Pharmaceuticals in Q1 2018 and held it in 7 quarters.
Bradley Foster & Sargent's Ionis Pharmaceuticals position peaked at $2.02M in Q1 2019.
349 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2022.

Based on Bradley Foster & Sargent's 13F filing for Q2 2022, filed 11 Aug 2022.